Structure Therapeutics Inc. 4

FMR LLC-affiliated F-Prime funds sold a combined 17,452 ADSs of Structure Therapeutics Inc. at about $50.07 per ADS on July 22, 2026, as part of modest portfolio-trimming sales.

On July 22, 2026, FMR LLC, reporting as a control person for affiliated F-Prime funds, filed a Form 4 for sales of Structure Therapeutics Inc. American Depositary Shares (ADSs) at a weighted-average price of $50.07 per ADS. F-Prime Capital Partners Life Sciences Advisors Fund VI LP sold 1,367 ADSs (representing 4,101 ordinary shares), and F-Prime Capital Partners Life Sciences Fund VI LP sold 16,085 ADSs (representing 48,255 ordinary shares), for total gross proceeds of roughly $876,000. After these transactions, the reporting group continued to hold significant indirect positions, including 20,502 ordinary shares via the Advisors Fund, 241,275 ordinary shares via the Fund, and a larger pool of 4,546,674 ADSs and 1,515,558 ordinary shares held by persons and entities whose shares are subject to reporting by FMR LLC, indicating these were modest portfolio-trimming sales rather than a major reduction of FMR’s overall economic exposure.

Filing Facts

CIK

1888886

Ticker

GPCR

Form

4

Source Type

fda

Accession

0001193125-26-315240

Alert Tier

6